title: Macular hole formation following photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Iwama
authors.forename: Sotaro
authors.initials: S
authors.lastname: Ooto
authors.forename: Akitaka
authors.initials: A
authors.lastname: Tsujikawa
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamashiro
authors.forename: Nagahisa
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002829:Choroid / Q000098:blood supply; D015862:Choroid Diseases / Q000188:drug therapy; D003131:Combined Modality Therapy; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007267:Injections; D008297:Male; D016491:Peripheral Vascular Diseases / Q000188:drug therapy; D010778:Photochemotherapy / Q000009:adverse effects*; D012167:Retinal Perforations / Q000209:etiology*; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000009:adverse effects*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide